OSE Immunotherapeutics Says Tedopi Combinations Meet Primary Endpoint in Phase 2 Lung Cancer Trial

Bitget2026/10/29 17:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

OSE Immunotherapeutics reported positive final Phase 2 Combi-TED results for Tedopi combinations in metastatic non-small cell lung cancer.
Results were presented October 25, 2026, at the European Society for Medical Oncology annual meeting in Madrid.
Both combinations met the primary survival endpoint; survival outcomes favored Tedopi with docetaxel or nivolumab over docetaxel alone.
Exploratory analyses favored the combinations but fell short of the predefined threshold for advancing to Phase 3; no unexpected safety signals emerged.
The ongoing ARTEMIA Phase 3 trial is evaluating Tedopi alone against docetaxel.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSE Immunotherapeutics SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610291330OMX_____CNEWS_EN_GNW1001280741_en) on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

OSE Immunotherapeutics Says Tedopi Combinations Meet Primary Endpoint in Phase 2 Lung Cancer Trial

You may also like

Crypto prices